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I t  73-3 Hel ical  Atheractomy for In-Brant Restenosis: Acute and 
Long-Term Results From the Helixcision TM 
EndoLumlnal In-Stent Excision (HELIX I) International 
Feas ib i l i ty  Trial 
Mamoo Nakamura, Andrew J. Carter, Yasuhiro Honda, Alexander Abizaid, Arne Torte, 
Eberhard Grupa, Paul G. Yock, Alan C. Yaung, Peter J. Fitzgerald, The HELIX I 
Investigators, Stanford Universi~ Stanford, California. 
Background: The Helixcision TM EndoLuminal In-stent Excision (HELIX I) Intemational 
Feasibility trial is a prospective multi-center egistry to test a new helical atherectomy 
device for the treatment of in-stent restenosis. The primary endpoint of this study is the 
safety of this device defined as major adverse cardiac events (MACE) at 30 days. The 
secondary endpoints are target lesion revascularization (TLR) and angiographic binary 
restenosis at 6-month follow-up. 
Methods: In HELIX f, 32 in-stent restenosis lesions (17.2±11.4 mm in mean lesion 
length) in 32 patients ware treated with Halixcision followed by balloon angioplasty. The 
debulking efficacy was assessed with serial IVUS (pra, post-HeUxcision and post-adjunc- 
tive balloon) in a subset of 18 lesions. To further investigate the longitudinal efficacy, 3D 
analysis was also performed in 12 lesions with automated pullback to calculate average 
cross-sectional areas across the stant. 
Reaults: At baseline, the angiographic reference diameter was 2.60±0.46 mm. Minimum 
lumen diameter improved from 0.84±0.33 to 2.19±0.41 mm (p<0.0001). IVUS showed a 
relative reduction of intimal area (IA) by 39±19% (from 4.99±2.04 to 2.98±1.47 mm 2, 
p<0.0001) after Helixcision; adjunctive balloon angioplasty resulted in a total reduction of 
50±16% (to 2,44±1.09 mm 2) at the site of minimum lumen area. The degrees of IA 
reduction were closely similar in 3D analysis. To date, 30-day and 6-month clinical follow- 
up is available in 97% and 72% of the enrolled patients, respectively. At 30-day follow-up, 
no MACE was reported except for CK elevation in 2 patients (6%) within f day after pro- 
cedure. TLR within 6 months was performed in 6 patients (26%). Angiographic follow-up 
data will be also presented. 
Conclusions: Preliminary results of HELIX I indicate that helical atherectomy is safe and 
feasible for the treatment of in-stant restenosis. The concordant results between 2D and 
3D IVUS analyses suggest that this unique technology can achieve uniform longitudinal 
dabulking throughout he stant. The long-term outcomes appeared to be favorable, con- 
sidering the relatively diffuse lesion morphology in the small vessels in this trial. 
1173-4 The Influence of Diabetes on Long-Term Cl in ica l  
Outcome Following Percutaneoua Coronary 
RevascularlzaUon for Single Vessel Disease 
Meyer Elbaz. Dakher Lahidheb, Robert Hobeika, Philippe Uzzan, Eric Maupas, Joelle 
Fourcada, Jacques Poel, Didiar Cardd, Cardiology, Purpan Hospital Toulouse, France. 
Background : Diabetics have more often extent of coronary artery disease (CAD) and 
less favorable outcomes after any form of revasculadzation. However, in comparison with 
non diabetic (ND) patients, the long-term survival in diabetic (D) patients type II who 
underwent parcutanaous coronary intervention (PCI) for single vessel disease (SVD) has 
not been validated. 
Methods : Between April 1995 and March 1996, we analyzed a cohort of 533 consecutive 
patients with SVD who were treated with PCI and divided into ND (n = 437 pts) versus D 
(n = 87 pts) groups respectively. Clinical and angiographic baseline characteristics were 
similar between the two groups and global left ventricular(LV) function was sub-normal 
(54.6 % versus 55.8 %, p = ns). 
Mean follow-up interval was 50 ± 13.5 months. The primary end-point of follow-up was 
death of any cause and secondary end-point was cardiac death, target lesion revascular- 
ization (TLR), major adverse cardiac events (MACE) and extent of CAD. Survival rates of 
the two groups were estimated by the Kaplan-Meier method. 
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ND Group D Group p 
(n = 437 pts) (n = 87 pts) 
Death 44 (10.1%) 17 (19.5 %) 0.01 
Cardiac Death 22 (5 %) 16 (18.4 %) < 0,0001 
TLR 83 (19 %) 16 (18.4 %) ns 
MACE 139 (31.8 %) 39 (44.8 %) 0.02 
Extent of CAD 49 (11.2 %) 18 (20.7 %) 0.009 
Conclusion ; In comparison with non diabetic patients and in spite of pre-spacified CAD 
(PCI for SVD), diabetes mellitus is associated with worse long-term outcome and 3-fold 
higher rate of cardiac mortality. 
1173-5 Impact  o f  Renal Function on Morbidity and Morta l i ty  
After Percutaneous Saphenous Vein Graft Intervention 
Luis Gruberg, Nail J. Weissman, Augusto D. Pichard, Ron Waksman, Kenneth M. Kent, 
Lowell F. Satler, William O. Suddath, Hongshang Wu, Joseph Lindsey, Jr., Washington 
Hospital Center, Washington, DisL of Columbia, Rambam Medical Center, Hails, israel. 
Background: Percutaneous coronary intervention in patients with chronic renal insuffi- 
ciency (CRI) and native coronary artery disease is often problematic, marred by 
increased mortality, morbidity and revascularization procedures. Little is known about the 
effect of CRI on patients who undergo saphenous vein graft (SVG) intervention. Meth- 
ods: We analyzed 1,265 consecutive patients who underwent percutaneous SVG inter- 
vention and divided them into four groups based on calculated craatinine clearance 
(CrCI): Group 1, CrCI>70 ml/min (n=626); Group 2, CrCi=50-69 ml/rnin (n=357); Group 3, 
CRC1=30-49 ml/min (n=228) and Group 4 ; CrCI<30 ml/min (n=54). Patients on dialysis 
were excluded from the study. Results: Patients with lower CrCI were more often older, 
female, diabetics and had worse left ventricular function. Overall immediate procedural 
success was similar for all groups. In-hospital and one-year outcomes are shown in the 
Table. By multivariate regression analysis, CrCI was an independent predictor of late 
mortality. Conclusion: This study suggests that renal function is a primary determinate in 
short- and long-term survival in patients undergoing percutaneous SVG intervention and 
there is a clear relationship between CrCI and cardiovascular outcome. 
Group I Group 2 Group 3 Group4 p 
(n=626) (n=357) (n=228) (n=54) 
In-hospital death 0.3 % 1.5 % 2.2 % 7.1% <0.001 
In-hospital cardiac death 0.1% 1.1% 1.5 % 2.4 % 0.002 
12-month death 7.1% 8.0 % 19.0 % 36.7 % <0.001 
12-month cardiac death 66.0 % 80.7 % 63.2 % 54.6 % <0.001 
1173-6 Ef fect  of Postmenopausal Hormone Therapy on Major  
Adverse Cardiac Events After Percutaneous Coronary 
Intervention: The HERS Trial 
Masrcor A. Khan. Michael G. Shlipak, Ming W. Liu, William J. Rogers, Feng Lin, Mark A. 
Hlatky, University of Alabama at Birmingham, Birmingham, Alabama, University of 
California San Francisco, San Francisco, California. 
OBJECTIVES: To determine the effect of post-menopausal hormone therapy (HRT) on 
coronary heart disease (CHD) events after percutaneous coronary interventions. 
BACKGROUND: In observational studies, HRT with estrogen has been associated with 
a reduced incidence of major adverse cardiac events (MACE) after percutaneous coro- 
nary interventions (PCI) in postmenopausal women. No clinical trial has studied the 
effects of post-menopausal HRT after percutaneous coronary intervention. 
METHODS: The Heart and Estrogen/progestin Replacement Study (HERS), was a ran- 
domized clinical trial of hormone therapy for CHD prevention in post-menopausal women 
with known CHD. During HERS follow-up, 357 participants underwent percutaneous cor- 
onary intervention, 175 in the HRT arm and 182 on placebo. This study compared the 
incidence of MACE subsequent to PCI among participants assigned to HRT and pla- 
cebo. 
RESULTS: Among the women who underwent PCI, baseline characteristics were similar 
between those in the HRT and placebo groups. Mean follow-up duration was 27 months 
for HRT group and 25 months for placebo group (p=0.50). During follow-up, 70 (40%) 
women in the HRT group and 72 (40%) women in the placebo group experienced a CHD 
event (RR=0.97; 95% Ch 0.70 - 1.35). No differences were observed in the incidences of 
target lesion rovascularization (27% vs. 30%; p=0.64), unstable angina (10% vs. 10%; 
p=0.90), myocardial infarction (7% vs 10%; p---0.31), or CHD death (6% vs. 5%; p=0.75). 
After multivariate analysis, only diabetes was a significant predictor of CHD events 
(RR=1.85; 95% Ch (1.26 - 2.72), 
CONCLUSION: In contrast to prior observational studies, HRT had no effect on major 
adverse Cardiac events after percutaneous coronary interventions in the HERS trial. 
1173-7 Predictors of Contrast Induced Nephropathy After 
Percutaneoua Coronary Intervention in Patients With 
and Without Chronic Renal Fai lure 
Ioannis lakovou, G. Dangas, A. J. Lansky, M. Negoita, I. Hjazi, D. Ashby, J. Forman, M 
Guiry, R. Brendwein, M. Losquadro, T. Limpijankit, G. W. Stone, J, W. Moses, M. B. Leon, 
R. Mehran, Cardiovascular Research Foundation, Lenox Hill Heart & Vascular Institute, 
New York, New York. 
Background: Contrast induced nephropathy (CIN) has been associated with unfavorable 
early and late outcome. We determined predictors of CIN in patients with and without 
chronic renal failure (CRF), defined as baseline serum craatinina >1,5 mg/dl. 
Methods and Results: Of a total 8268 consecutive patients who underwent PCI (Jan 
1994 to July 1999), 1431 (16.5%) developed CIN (25% rise in serum creatinine com- 
pared to pre-PCI). Creatinina clearance was calculated by the Cookcroft formula. 
Independent predictors of CIN derived by stepwise logistic regression analysis for both 
groups (Table). 
Conclusions. Baseline clinical characteristics and creatinine clearance (not serum craati- 
nine value) predict CIN development after PCI. Meticulous CIN preventive measures 
should be targeted in the high-risk patients. 
